Phase II Trouble

Phase II clinical trials are in trouble, says Pharmalot's Ed Silverman. According to a new study in Nature Reviews Drug Discovery, success rates for Phase II trials fell from 28 percent in 2006 and 2007 to 18 percent in 2008 and 2009. "The implication is that the overall attrition of late-stage drug development seems to be unsustainably high," Silverman says.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.